PEG-MGF
No published human study has tested PEG-MGF. One exact PubMed record names it. That paper is a review, not a PEG-MGF trial. The US FDA also says it found no data from people who used a drug product containing PEG-MGF. These findings were checked on 25 August 2026.
What is PEG-MGF?
PEG-MGF is sold as pegylated mechano growth factor. The literature links the name to IGF-1Ec, a form related to IGF-1. PMID 42395176 is the only exact PubMed record that names PEG-MGF. This identity claim was checked on 25 August 2026.
The review says most cited lab work concerns MGF itself or lab-made parts of MGF. That work does not test PEG-MGF as a drug. The paper reports no outside research funding. Fundacja Rozwoju Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu paid part of its publication fee. The fund had no role in the paper. The authors declared no business or financial conflict. They also disclosed AI use for language editing and the first literature screen. These disclosures were checked in the full text on 25 August 2026.
Has PEG-MGF been studied in people?
No peer-reviewed human study of PEG-MGF was found. Exact searches for PEG-MGF, PEG MGF, and PEGMGF each returned only PMID 42395176. Wider searches returned six more records. None of those records studied PEG-MGF. All seven records were opened and checked on 25 August 2026.
ClinicalTrials.gov returned no study under five exact PEG-MGF names. The search used working positive and negative controls. It was checked on 25 August 2026. The EudraCT pages opened, but their result counts could not be read. That gap is not reported as zero.
Evidence tier: D — in vitro, theoretical, or nothing. Findings about MGF itself are not assigned to PEG-MGF.
What has the US FDA published about PEG-MGF?
“Mechano growth factor pegylated (PEG-MGF)” appears in the US FDA table headed “Bulk drug substances nominated but withdrawn”. The FDA page says these substances were once in Category 2 under the interim rules and were then withdrawn by those who proposed them. PEG-MGF is not in the current Category 2 table. The first table holds the drugs that are now in Category 2. PEG-MGF is in the second table. That table has no date-added field and no 503A or 503B label. The row is not a drug approval or a ban. Its risk text still applies to the old nomination record. It shows what the FDA said when the drug was on that past list. The US FDA says compounded PEG-MGF may cause an immune response for some routes. It also points to peptide impurities and difficulty checking the active ingredient. These US findings were checked on 25 August 2026.
The US FDA says it found no human use data for drug products containing PEG-MGF by any route. The agency also says it lacks enough facts to know whether PEG-MGF would harm people. These are gaps in evidence, not reports that harm occurred.
What is PEG-MGF's regulatory status?
EU status: unclear. PEG-MGF was absent from the EMA central medicines report checked on 25 August 2026. That report does not cover every national approval in an EU member state.
Germany and Sweden remain recorded as unclear. Those fields were last checked on 17 August 2026.
Does PEG-MGF have a chemical identifier?
No PEG-MGF chemical ID is recorded. Controlled GSRS searches under five exact names returned no match on 25 August 2026. Mecasermin and MGF without PEG are different substances. They are not stand-ins for PEG-MGF.
Also known as: pegylated mechano growth factor.
When was PEG-MGF first documented?
A sound first-seen month has not been established. PMID 42395176 was published in 2026. It cites a marketing guide accessed on 21 July 2025. That citation proves an earlier mention, not the first use or sale of PEG-MGF. This date limit was checked on 25 August 2026.
What do users report?
No complete first-person PEG-MGF thread was found in the forum archive we could read. No forum quote or group claim is included.
→ What can be inside a grey-market vial → All compounds in the register